Vasculitis UK is helping the BIOVAS clinical trial to identify suitable participants.
The two-year trial is looking at the effectiveness of infliximab (INF), tocilizumab (TCZ) and rituximab (RTX).
Suitable patients will will have one of the following types of vasculitis:
- Giant cell arteritis
- Takayasu’s arteritis
- Polyarteritis nodosa
- Cogan’s syndrome
- Relapsing polychondritis
- IgA vasculitis
- Non-infective cryoglobulinaemic vasculitis.
Patients will not be able to take part if they have recently received a biologic drug, have a serious infection, or are pregnant.